Utilizing Digital Health to Promote Adherence to Combination Therapy Regimens in Renal Cell Carcinoma: A Clinical Update for Specialty Pharmacists
Bristol Myers Squibb and Exelixis, Inc.
Faculty Presenters
Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Associate Clinical Professor
Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut
Clinical Oncology Pharmacist
University of Connecticut Health Carole and Ray Neag Comprehensive Cancer Center
Farmington, Connecticut
Megan C. Rees, PharmD
Residency Program Director
Clinical Pharmacy Specialist - Oncology
Trellis Rx
Summa Health System
Akron, Ohio
Program Description
Renal cell carcinoma (RCC) is the most common kidney cancer in the United States, accounting for approximately 85% of cases. Specifically, the clear cell histology is the most common, and many patients with metastatic clear cell (mcc) RCC are treated with targeted therapies including tyrosine kinase inhibitors (TKIs), anti-vascular endothelial growth factor (VEGF) antibodies, mammalian target of rapamycin (mTOR) inhibitors, and immune checkpoint inhibitors (ICIs), potentially in combination with additional treatments. Specialty pharmacists are in a unique position to provide education to both patients and the medical team, and they can also assist in patients’ understanding of novel technologies to assist in adherence. This activity will provide an overview of preferred treatments for mccRCC and will emphasize the role pharmacists play in promoting positive patient outcomes through the use of digital health tools and platforms.
Target audience: Specialty, oncology, and health-system pharmacists
Type of activity: Application
Release date: December 23, 2020
Expiration date: June 23, 2022
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the clinical relevance of emerging clinical trial data in first-line treatment of metastatic clear cell renal carcinoma (mccRCC)
- Distinguish the role of specialty pharmacists in managing patients with mccRCC with immune checkpoint inhibitor-related adverse events
- Identify barriers to medication adherence and outcomes associated with low adherence in patients with mccRCC
- Determine how digital health tools and platform information can be used to improve outcomes in patients with mccRCC
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-403-H01-P. The activity is available for CE credit through June 23, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, has the following relevant financial relationship with commercial interest to disclose:
- Consultant – Postgraduate Healthcare Education, LLC
Megan C. Rees, PharmD, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™
Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Croom Taylor, PharmD, CPP; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
